Navigation Links
Rittal Corp. Joins the HP ProActive Insight Architecture Alliance
Date:5/29/2012

URBANA, Ohio, May 29, 2012 /PRNewswire/ -- Rittal Corp. today announced it is a founding member of the HP ProActive Insight Architecture (PIA) Alliance, selected by HP for its server rack technology developed to the HP standards and interfaces that contribute to the industry-transforming performance and reliability of HP ProLiant Generation 8 (Gen8).

HP ProActive Insight Architecture, now available in the new HP ProLiant Gen8 servers, transforms data center economics with built-in intelligence that improves performance and uptime, while lowering operating costs. As a founding member of the HP PIA Alliance, Rittal Corp. will continue to contribute to the elimination of common problems caused by human-to-technology interaction that lead to system downtime and data loss. Through embedded HP ProLiant Gen8 server technology, HP PIA Alliance members, along with HP, can evaluate data and other critical analytics to continually optimize and improve on business results.

The HP PIA Alliance brings together the collective value of the world's leading technology innovators to complement HP ProLiant Gen8 servers. Alliance members, drawn from leaders in memory, storage, I/O, power and infrastructure solutions, build technology components to HP Proactive Insight architecture standards and interfaces. These components help to analyze thousands of system parameters and automate processes that consume critical data center resources. Additionally, they provide insight into aspects of application performance and IT infrastructure optimization that had once been nearly impossible to capture and utilize.

"As one of the original participants in the development of the industry-standard 19" rack design, Rittal is fully committed to the process of continuous innovation required to meet the growing requirements of the data center," noted Doug Peterson, president, Rittal Corporation. "We're extremely pleased to participate in HP's effort to develop the technology
'/>"/>

SOURCE Rittal Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rittals Hygienic Design Enclosures Meet the Challenges of Sensitive Environments
2. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
3. Cantel Medical Corp.s Crosstex Subsidiary Addresses School MRSA Concerns With SaniTyze(TM) Brand Hand Sanitizer and Sanitex(R) Surface Disinfecting Line of Products
4. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
5. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
6. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
7. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
8. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
9. BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
10. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
11. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015 Biosensors ... BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, ... announced financial results for its first fiscal quarter ... Quarter Highlights and Recent Developments: ... in improving its cost structure, driven by lower ...
(Date:8/3/2015)... BOULDER, Colo., Aug. 3, 2015  Array BioPharma ... for the fourth quarter and full year of ... Ron Squarer, Chief Executive Officer of Array, noted, ... Phase 3, are on track for regulatory submissions ... in BRAF-mutant melanoma and BRAF-mutant colorectal cancer further ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
Breaking Medicine Technology:Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... 04, 2007 /PRNewswire/ -- Novagali Pharma, an,emerging ... positive results from the Phase III,clinical study ... (VKC). In this orphan disease, it was ... improved in patients,receiving Vekacia(R). Furthermore, the tolerability ...
... Phase III study of ERBITUX with,chemotherapy in ... primary endpoint of improving overall survival --, ... ImClone,Systems Incorporated and Bristol-Myers Squibb Company announced,today ... of ERBITUX(R) (Cetuximab),combined with platinum-based chemotherapy met ...
Cached Medicine Technology:Novagali Pharma Announces Positive Vekacia Clinical Results From,Pivotal Phase III Trial in Vernal Keratoconjunctivitis 2Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 2Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 3Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 4Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 5Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 6Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 7Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 8Survival Data Available From Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 9
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... as one of 20 finalists for America’s Favorite Veterinarian. The contest is put ... by a judging committee from 500 nominees. Nominees were evaluated on community involvement, ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... of higher learning, announced today that its RN to BSN and Master ... been awarded full accreditation through June 2020 from the Commission on Collegiate ...
(Date:8/4/2015)... ... 04, 2015 , ... Continuing Education Company (CEC) ... interaction simulation session entitled "NOACS: What the Evidence Shows in Managing AFib, ... Inc. and EDUmotion US LLC. , This special activity was recently presented during ...
(Date:8/4/2015)... ... 2015 , ... IN AMERICA and the program's host, James ... affects millions of Americans every single year. To help people obtain a better ... the latest segment produced with the assistance of several top medical professionals. ...
(Date:8/4/2015)... ... 04, 2015 , ... Healthcare IT News (HITN), ... in healthcare and technology markets, today announced significant spikes in website traffic and ... Health Record (EHR) decision. The DOD related numbers solidify HITN’s status as the ...
Breaking Medicine News(10 mins):Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2
... men treated with a combination of radiation seed implants ... cured of their disease 15 years// following their treatment, ... Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO. ... at the Seattle Prostate Institute. Doctors wanted to look ...
... circumcision procedure could reduce 50% of the HIV infection rate ... number of Ugandan men seeking it.// , ... reports, out of which nearly half were adults. Less than ... Institutes of Health found that new HIV infections among circumcised ...
... alleviate symptoms of early-stage Parkinson's disease, and may be ... the brain disorder,// researchers said., ,A neupro patch ... to study its effects on 277 people in Canada ... is designed to convey a drug called rotigotine ...
... Parkinson's appear to increase the risk of heart valve disease, ... disorder of the central nervous system that often impairs motor ... that keep blood flowing in the right direction through the ... blood may not move the way it should., ,The ...
... is the final awakening' - Walter Scott// ... the former president of Iraq, Saddam Hussein, was sent to the ... the fact that he slaughtered 148 fellow countrymen, who were Shias, ... put to use in all societies to wipe out political dissent. ...
... Inner city dwellings were thought to be far cleaner and ... say this is not true- inner cities are a haven// ... and TNS analyzed smoking and disease rates and dietary habits ... The analysis revealed that towns such as Merthyr Tydfil in ...
Cached Medicine News:Health News:'Hooded Horror': Death by Hanging 2Health News:'Hooded Horror': Death by Hanging 3
The CA method used on the Dade Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of calcium in serum....
For the quantitative in vitro determination of Total Protein in serum and plasma...
The LDH method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of lactate dehydrogenase activity in serum or plasma...
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Medicine Products: